

EVALUATION OF (ALPHA) – METHYLACYL–COENZYME A RACEMASE AS A NEWLY SUGGESTED MARKER FOR DIAGNOSIS AND FOLLOW UP OF CANCER PROSTATE

Thesis

*Submitted for the Partial Fulfillment of M.D. Degree
in Clinical and Chemical Pathology*

By

Rania Farouk Mohamed El-Awady
*M.B., B.Ch., M.Sc. Clinical and Chemical Pathology
Faculty of Medicine, Ain Shams University*

Supervised by

Professor/ Hany Sobhy Rufail
*Professor of Clinical and Chemical Pathology
Faculty of Medicine, Ain Shams University*

Professor/ Mona Fathy Youssef
*Professor of Clinical and Chemical Pathology
Faculty of Medicine, Ain Shams University*

Professor/ Karim Yehia Ali Shaheen
*Professor of Clinical and Chemical Pathology
Faculty of Medicine, Ain Shams University*

Doctor/ Nermine Helmy Mahmoud
*Assistant Professor of Clinical and Chemical Pathology
Faculty of Medicine, Ain Shams University*

Doctor/ Hany Hamed Gad
*Assistant Professor of Urology
Faculty of Medicine, Ain Shams University*

**Faculty of Medicine
Ain Shams University
2013**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ
﴿وَأَنْزَلَ اللَّهُ عَلَيْكَ الْكِتَابَ
وَالْحِكْمَةَ وَعَلَّمَكَ مَا لَمْ تَكُن تَعْلَمُ
وَكَانَ فَضْلُ اللَّهِ عَلَيْكَ عَظِيمًا﴾

صدق الله العظيم
النساء .. آية رقم ١١٣



Acknowledgement

First of all, thanks to **GOD** for giving me the power to accomplish this work and for achieving any work in my life.

I would like to express my deepest gratitude to my honored **Professor/ Hany Sobhy Rofael**, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain-Shams University, for his kind help throughout this study and his guidance during the work.

Also I would like to express my thanks and appreciation to **Professor/ Mona Fathy Youssef**, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain-Shams University, for her kind help, valuable guidance, assistance and encouragement.

My deep gratitude, respect and appreciation are expressed for **Professor/ Karim Yehia Aly Shaheen**, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain-Shams University, for his continuous valuable guidance, encouragement and endless support.

I am very grateful to **Dr. Nermine Helmy Mahmoud**, Assistant Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain-Shams University, for her great guidance, help, valuable advices and continuous encouragement throughout the whole work. I wish to express to her my unlimited thanks.

My deepest gratitude and appreciation to **Dr. Hany Hamed Gad**, Assistant Professor of Urology, Faculty of Medicine, Ain-Shams University, for his great help in performing the practical part of this thesis and for his valuable information and advices.

Actually no words are sufficient to express my love and faithful thanks to my family, especially my mother and my husband, who didn't stop encouraging and helping me.

Finally to my late Dad to whom I owe everything I accomplished in my life, thank you.

✍ **Rania Farouk El-Awady**

List of Contents

<i>Title</i>	<i>Page No.</i>
List of Abbreviations	iv
List of Tables	viii
List of Figures	x
Introduction.....	1
Aim of the work.....	3
<u>Review of literature</u>	
I. Prostate Cancer	4
A. Epidemiology	4
1. Incidence.....	4
2. Risk Factors	6
B. Prostate Cancer Carcinogenesis.....	19
1. Chromosomal Alteration.....	20
2. Tumor Suppressor Genes.....	22
3. Oncogenes	24
4. DNA Repair	26
5. Aging and Telomerase	27
6. Growth Factors.....	29
7. Metastasis Suppressor Genes.....	32
8. DNA Methylation	35
9. Androgen Receptor.....	36
10. Stress Response Genes.....	40
11. Detoxification and Fatty-acid Metabolism Genes.....	41

List of Contents (Cont...)

<i>Title</i>	<i>Page No.</i>
C. Classification of Prostate Cancer.....	43
1. <i>Pathological Types of Prostate Cancer</i>	43
2. <i>Histological Grading of Prostate Cancer</i>	48
D. Staging of Prostate Cancer	50
E. Spread of Prostate Cancer	54
1. <i>Local Spread</i>	54
2. <i>Lymphatic Spread</i>	54
3. <i>Haematogenous Spread</i>	55
F. Screening of Prostate Cancer	55
1. <i>American Cancer Society Screening Guidelines of Prostate Cancer</i>	56
2. <i>Screening Tools</i>	57
G. Diagnosis of Prostate Cancer	71
1. <i>Clinical Presentation</i>	71
2. <i>Physical Examination</i>	72
3. <i>TRUS and TRUS-Guided Biopsy</i>	74
4. <i>Imaging</i>	76
5. <i>Laboratory Diagnosis</i>	79
H. Treatment and Follow Up of Prostate Cancer	86
I. Prognosis of Prostate Cancer.....	88
II. Alpha-Methylacyl-CoA Racemase (AMACR).....	90
A. Nature and Structure	90
B. Expression of AMACR.....	92

List of Contents (Cont...)

<i>Title</i>	<i>Page No.</i>
C. Physiological Function of AMACR/P504S.....	92
D. Clinical Significance of AMACR	95
<i>1. In Benign Disorders.....</i>	<i>95</i>
<i>2. In Tumors.....</i>	<i>96</i>
E. Methods of Assay of AMACR	110
<i>1. Western Blot Analysis.....</i>	<i>110</i>
<i>2. Quantitative Real-time PCR (RT-PCR).....</i>	<i>111</i>
Subjects and Methods.....	115
Results	146
Discussion.....	176
Summary	191
Conclusion	200
Recommendations	201
References	202
Arabic summary	—

List of Abbreviations

A.....	Alanine
A2M.....	α 2-macroglobulin
AAH.....	Atypical adenomatous hyperplasia
ACT	α 1-Antichymotrypsin
AJCC.....	American joint committee on cancer
AMACR	Alpha-methylacyl-CoA racemase
API	α 1-protease inhibitor
AR.....	Androgen Receptor
AUC.....	Area under curve
bp.....	Base-pair
BPH.....	Benign prostatic hyperplasia
BPSA.....	Benign PSA
BRCA	Breast cancer gene
C-CAM	Cell adhesion molecule
CDK.....	Cyclin dependent kinase
CDKN	Cyclin dependent kinase
cDNA.....	Complementary deoxyribonucleic acid
CGH	Comparative genomic hybridization
CLEIA.....	Chemiluminescence enzyme immunoassay
COX2.....	Cyclooxygenase (COX2) enzyme
CT.....	Computed tomography
CTC	Circulating tumor cells
DELFI.....	Dissociation-enhanced lanthanide fluorescent immunoassay
DEPC	Double distilled diethyl pyrocarbonate
df.....	Degree of freedom
DNA	Deoxyribonucleic acid
dNTP.....	Deoxynucleotide triphosphate
DPC	Diagnostic Products Corporation
DRE.....	Digital rectal examination
DTT	Dithiothreitol
EGF	Epidermal growth factor

List of Abbreviations (Cont...)

EGFR	Epidermal growth factor receptor
ELISA	Enzyme linked immunosorbent assay
FAS.....	Fatty acid synthase
FDA.....	Food and Drug Administration
FDG.....	Fluorodeoxyglucose
FGF	Fibroblast growth factor
FGFR	Fibroblast growth factor receptor
FIA.....	Fluorescent immunoassay
FISH	Fluorescence in situ hybridization
FISH.....	Fluorescent in situ hybridization
FN.....	False negative
FP	False positive
fPSA	Free prostate-specific antigen
GAPDH.....	Glyceraldehyde 3 phosphate dehydrogenase
GF.....	Growth factor
GPI	Glycosylphosphatidylinositol
GSTP1	Glutathione S-transferase
H and E.....	Haematoxylin and eosin
Hcl	Hydrochloric acid
HGPIN.....	High-grade prostatic intraepithelial neoplasia.
hK/ KLK	Human Kallikrein
HK2.....	Human glandular kallikrein-2
HMWCK.....	High-molecular-weight cytokeratin
HSP	Heat Shock Proteins
IGF	Insulin-like growth factor
IGF	Insulin-like growth factor
IGFBP	Insulin – like growth factor binding protein
iPSA	Inactive PSA
L.....	Leucine
LHRH	Leuteinizing hormone-releasing hormone

List of Abbreviations (Cont...)

LNCap	Prostate carcinoma cell line
LOH.....	Loss of heterozygosity
mABs.....	monoclonal antibodies
MRI	Magnetic resonance imaging
MSGs	Metastasis-suppressor genes
MSMB.....	Microseminoprotein beta
mTOR	mammalian target of rapamycin
NASBA	Nucleic acid sequence-based amplification
nf.....	nuclear factor
NF.....	Nuclear factor
p	probability
P	Proline
p	Short arm of chromosome
PAP	Prostatic acid phosphatase
PC	Prostate cancer
PCA3	Prostate cancer antigen 3
PCGP	Prostate cancer genetics project
PCPT	Prostate Cancer Prevention Study
PCR	Polymerase chain reaction
PEBP1	Phosphatidylethanolamine binding protein1
PET	Positron emission tomography
PH.....	Potential hydrogen
PIN	Prostatic intraepithelial neoplasia
PPV	Positive predictive value
PSA.....	Prostate specific antigen
PSCA.....	Prostate stem cell antigen
PSMA.....	Prostate-specific membrane antigen
q	Long arm of chromosome
R.....	Arginine
RB.....	Retinoblastoma tumor suppressor gene

List of Abbreviations (Cont...)

RIPA buffer	Radio immunoprecipitation assay buffer
RNase.....	Libonuclease L
ROC.....	Receiver-operating characteristic
RR.....	Relative risk
rs.....	Spearman's rank correlation coefficient
RT-PCR.....	Reverse transcriptasepolymerase chain reaction
S.....	Serine
SD.....	Standard deviation
SEER.....	Surveillance Epidemiology and End Results
SF	Survival factor
SNPs	Single nucleotide polymorphisms
SNPs	Single nucleotide polymorphisms
STA.....	Tsignal transducers and activators of transcription
TAE	Tris acetate EDTA
TGF- α	Transforming growth factor- α
TGF- β	Transforming growth factor- β
TLC	Total leucocytic count
TN.....	True negative
TNM.....	Tumor-Node-Metastasis system
TP	True positive
tPSA.....	Total prostate-specific antigen
TRPM8.....	Transient receptor potential cation channel subfamily M member 8
TRUS	Transrectalultrasonography
TURP	Trans-urethral resection of the prostate
UICC	Union forInternational cancer control
UV	Ultra violet
β -ME.....	β - Mercaptoethanol
(1,25-(OH) ₂ -D3).....	1,25-dihydroxy-vitamin D ₃

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (1):	Prostate Cancer Susceptibility Genes.....	9
Table (2):	Family History and Risk of Prostate Cancer	10
Table (3):	Tumor node metastasis (TNM) stage definitions for prostate cancer	51
Table (4):	TNM anatomic stage prognostic groups for prostate cancer	53
Table (5):	American Cancer Society Screening Guidelines of Prostate Cancer.....	57
Table (6):	Factors affecting PSA.....	59
Table (7):	Comparison of presenting symptoms of prostate cancer and benign prostatic hyperplasia.....	72
Table (8):	Classification of PC Patients according to Gleason Score.....	116
Table (9):	Classification of PC Patients according to TNM Staging.....	117
Table (10):	RT-PCR for AMACR detection.....	132
Table (11):	Descriptive Statistics of the Various Studied Parameters in All Studied Groups	156
Table (12):	Statistical Comparison between the Various Studied Parameters in All Studied Groups using Kruskal-Wallis Test (H)	157
Table (13):	Statistical Comparison between All Groups and Healthy Controls Regarding the Various Studied Parameters	158
Table (14):	Statistical Comparison between Different PC Subgroups and BPH Subgroup Regarding All Studied Parameters	159
Table (15):	Statistical Comparison between Different PC Patients' Subgroups Regarding All Studied Parameters	160

List of Tables (Cont...)

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (16):	Statistical Comparison between Organ Confined +Metastatic PC and the whole Control Group Regarding All Studied Parameters	161
Table (17):	Descriptive and Statistical Comparison of Percent of Increased Expression of AMACR	162
Table (18):	Statistical Comparison between Low Grade and High Grade Prostate Cancer Patients Regarding All Studied Parameters	163
Table (19):	Statistical Comparison between T2 and T4 Prostate Cancer Patients Regarding All Studied Parameters	164
Table (20):	Correlation Study between Different Studied Parameters in BPH Subgroup.....	165
Table (21):	Correlation Study between Different Studied Parameters in Prostate Cancer Patients' Collectively	166
Table (22):	Diagnostic Performance of the Different Studied Parameters in Discriminating Organ Confined PC and Metastatic PC from the Healthy Control Subgroup.	168
Table (23):	Diagnostic Performance of the Different Studied Parameters in Discriminating Organ Confined PC and Metastatic PC from PC Subgroup in Remission	170
Table (24):	Diagnostic Performance of the Different Studied Parameters in Discriminating Organ Confined PC Subgroup from Metastatic PC subgroup.	172
Table (25):	Diagnostic Performance of the Different Studied Parameters in Discriminating Organ confined PC and Metastatic PC from BPH Subgroup.	174

List of Figures

<i>Fig. No.</i>	<i>Title</i>	<i>Page No.</i>
Fig. (1):	Incidence of Prostate Cancer: International Comparisons	5
Fig. (2):	Most Common Cancer among Egyptian Males NCI 2002-03 combined.....	6
Fig. (3):	Age-specific SEER incidence rates for prostate cancer, for 2000-2003	7
Fig. (4):	Possible pathway for human prostate cancer progression	20
Fig. (5):	Androgen receptor signaling in normal and malignant prostate cells.....	38
Fig. (6):	Prostatic carcinoma, adenocarcinoma.....	43
Fig. (7):	Features of small cell carcinoma.....	44
Fig. (8):	Prostatic carcinoma, transitional cell type	45
Fig. (9):	Adenocarcinoma of the prostate with mucinous fibroplasia.....	46
Fig. (10):	The signet ring cell appearance.....	47
Fig. (11):	Gleason grading of prostate cancer.....	49
Fig. (12):	Molecular forms of prostate-specific antigen (PSA).....	64
Fig. (13):	Human kallikrein gene map.	80
Fig. (14):	The AMACR gene location	91
Fig. (15):	The human AMACR gene (side, front and top views).....	91
Fig. (16):	The central role of AMACR	94
Fig. (17):	Schematic presentation of the reaction mechanism of AMACR.....	95
Fig. (18):	Prostate needle biopsy specimen showing characteristic immunohistochemical staining patterns of α -methylacyl coenzyme A racemase (AMACR) between malignant and benign glands.....	102

List of Figures (Cont...)

<i>Fig. No.</i>	<i>Title</i>	<i>Page No.</i>
Fig. (19):	Schematic outline for the diagnosis of small, focal prostate carcinoma on needle biopsy by basal cell markers and AMACR/P504S immunohistochemical analysis.....	104
Fig.(20):	The procedure of RNA extraction.....	123
Fig. (21):	Electrophoretic separation of PCR product for AMACR mRNA	135
Fig. (22):	ROC curve analysis showing the diagnostic performance of all studied parameters in discriminating Organ Confined PC and Metastatic PC from healthy control subgroup.....	167
Fig. (23):	ROC curve analysis showing the diagnostic performance of all studied parameters in discriminating Organ Confined PC and Metastatic PC from PC in Remission Subgroup.	169
Fig. (24):	ROC curve analysis showing the diagnostic performance of all studied parameters in discriminating Organ Confined PC subgroup from Metastatic PC subgroup.....	171
Fig. (25):	ROC curve analysis showing the diagnostic performance of all studied parameters in discriminating Organ Confined PC and Metastatic PC from BPH subgroup.	173
Fig. (26):	Box Plot for AMACR in all studied groups.	175

INTRODUCTION

Prostate cancer is the fourth most common male malignancy and the second leading cause of male cancer-related death (*Samuels et al., 2003*). Small prostatic carcinomas were detected in 30% of men between 30 and 49 years old, 40% of males over age of 50, and 64% of men over 60 years old (*Sokoloff et al., 2004*). For this reason, an annual screening is generally recommended for all men over the age of 50.

Screening of prostate cancer on a large scale requires noninvasive methods of detection and the use of reliable, and clinically validated markers (*Galina et al., 2005*). Prostate cancer screening is currently based on digital rectal examination (DRE), prostate-specific antigen (PSA) monitoring, and transrectal ultrasound (TRUS) with TRUS- guided biopsy for morphologic examination as the reference standard (*Miller et al., 2002*). However, none of these standard methods is sufficiently sensitive nor specific for prostate cancer, which makes early detection of the disease difficult (*Gao et al., 2003*).

Several studies have suggested that detection of circulating tumor cells can be useful in the staging of